CD3G抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Raji cells using CD3G mouse mAb (green) and negative control (red).    

  
  

The CD3G antibody targets the CD3γ (CD3 gamma) chain, a critical component of the T-cell receptor (TCR) complex. CD3γ, encoded by the CD3G gene, is part of the CD3 family (CD3γ, δ, ε, ζ) that associates with the TCR to form a functional receptor on T cells. This complex plays a central role in adaptive immunity by linking antigen recognition to intracellular signaling. The CD3γ chain pairs with CD3ε to form heterodimers, which, along with CD3δε and ζζ homodimers, stabilize TCR expression and transduce activation signals via immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domains.

CD3G antibodies are widely used in research to study T-cell development, activation, and signaling. They enable detection of CD3γ expression in flow cytometry, immunohistochemistry, or Western blotting, helping to characterize T-cell subsets or diagnose T-cell-related disorders. Therapeutic CD3G-targeting antibodies are less common than those targeting CD3ε or CD3 pan-markers (e.g., OKT3), but they may have niche applications in modulating immune responses. Dysregulation of CD3γ has been implicated in immune deficiencies and autoimmune diseases, making it a potential biomarker. Additionally, CD3 antibodies are pivotal in bispecific T-cell engagers (BiTEs) or chimeric antigen receptor (CAR) T-cell therapies, where they redirect T cells to tumor antigens. CD3G-specific tools remain essential for dissecting TCR complex dynamics and developing targeted immunotherapies.